April 7, 2021
A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity
DRUG: Pembrolizumab
ACCRUAL STATUS: Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATOR:
David Kirsch, MD, PhD
Professor, Radiation Oncology / Professor of Pharmacology and Cell Biology
Duke University
CLINICALTRIALS.GOV IDENTIFIER: NCT03092323
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
To learn more about this study view Dr. Kirsch’s SARC032 presentation at the 2021 SARC Semiannual Meeting:
To contact the study research staff: